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ABSTRACT
The purpose of these studies was to enhance mucosal and
systemic antibody production in response to increased local
residence time of a whole inactivated influenza virus admin-
istered as a dry powder nasal vaccine formulation. Spray-
freeze-drying (SFD) particles suitable for nasal delivery were
characterized for physico-chemical properties and stability.
Mucoadhesive compounds (MA) were characterized for their
effects on nasal residence time of vaccine powders in rats
compared with published in vitro data and elicited immune
responses. SFD particles (D50 = 26.9μm) were spherical
with a specific surface area of 1.25 m2/g. Thermal analysis
indicated SFD powders were amorphous and demonstrated
improved stability with respect to liquid formulations under
various storage conditions. In vitro physico-chemical stud-
ies and in vivo scintigraphic imaging experiments indicated
sodium alginate (SA) and carboxymethylcellulose-high
molecular weight (CMC-HMW) powder formulations most
significantly increased residence time in Brown Norway rats.
Intramuscular delivery provided equivalent serum antibody
titers to intranasal (IN) powder without MA, in the presence
of CMC-HMW, SA, and hydroxypropyl methylcellulose
(HPMC-HMW) after initial dosing and all formulations ex-
cept IN powder with chitosan after boosting. IN liquid pro-
vided equivalent serum antibody titers to all IN powders after
the initial vaccination and significantly greater serum anti-
body titers than IN powder with chitosan after boosting.
Trends were consistent between residence time studies and
immune response; however, no statistically significant differ-
ences between powder and liquid formulations were ob-
served. It was concluded that enhanced serum and mucosal
antibody responses were elicited by a dry powder nasal vac-
cine, specifically, administered in the presence of sodium
alginate.
KEYWORDS: intranasal, powder, influenza, vaccine,
mucoadhesive, spray-freeze-dryingR
INTRODUCTION
There is growing interest in the development of stable pow-
der vaccine formulations and delivery technologies to over-
come refrigerated storage and distribution (ie, “cold chain”)
requirements associated with liquid-based vaccine stability
and delivery. Dry powder formulations are potentially supe-
rior to liquid formulations in that they do not support micro-
bial growth and are more stable, eliminating the necessity of
the cold chain, thereby facilitating mass vaccination particu-
larly in the developing world.1-5 There is an urgent need not
only to overcome cold chain requirements (for improved
stability), but also to provide single-use, nonrefillable deliv-
ery technologies that require minimal training. Intranasal ad-
ministration offers protection from influenza, since the virus
uses the nasal route of entry to the host and intranasal (IN)
vaccine elicits both a local and systemic immune response.
This approach may ultimately provide a safe and effective
alternative to the currently available influenza vaccines.
Earlier work was completed on a powder vaccine formula-
tion suitable for nasal delivery that was obtained by lyophi-
lization followed by milling and sieving under optimized
conditions.6,7 However, when delivered in vivo, the nasal
immunoglobulin A (IgA) responses elicited by IN powder
delivery were more variable than those induced by the liquid
vaccine.7 This variability may be explained, in part, by the dif-
ferences in particle size distribution and morphology observed
for these powders, leading to less reproducibility in emitted dose.
Milling of lyophilized cakes with large pores produced from
long channels formed by the crystallization and removal of
water resulted in the production of needle-like particles, which
were difficult to blend uniformly with other excipients. Al-
ternative methods of manufacture, such as spray-freeze-drying
(SFD) could potentially improve powder performance.
SFD, which combines the methods of spray-drying and
freeze-drying, was developed recently.8-13 This process is
initiated by spraying liquid droplets, usually aqueous solu-
tions, into liquid nitrogen, thus freezing them. The frozen par-
ticles are lyophilized at low temperature and pressure,
eliminating the potential for heat damage and degradation
of the solute. SFD frequently produces large porous parti-
cles with different aerodynamic properties than spray-
dried particles.11 Ideally, SFD particles are spherical and in a
narrow particle size range. They rarely require further particle
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size reduction (if required this is limited to deaggregation), min-
imizing the potential loss of activity, and rendering them suitable
for blending with an added mucoadhesive compound (MA).
Residence time on the nasal mucosa is a determinant of
effectiveness of vaccine delivery and response.14 To afford
protection, vaccines must present antigen to the target nasal-
associated lymphoid tissue (NALT). Mucoadhesive com-
pounds have been studied to prolong the residence time on
a mucosal surface14-21; however, most of these systems use
liquid formulations containing MA in solution. Powder sys-
tems require dissolution/hydration to occur for the system to
be effective in impeding mucociliary clearance. Release of
the active component from a powder to the nasal cavity must
take into account several factors, including wettability, dis-
solution rate, and the interaction between adjacent MA par-
ticles and mucus.
The present work involved the manufacture and develop-
ment of a dry-powder, inactivated, heat-stable influenza vac-
cine for nasal delivery that was intended to overcome the
shortcomings of currently marketed influenza vaccines (cost
of administration, need for refrigeration). Powders were man-
ufactured by SFD and evaluated for their physico-chemical
properties and storage stability. Since the antigen used in this
study is a whole inactivated virus, the term stability is used
to indicate retention of bioactivity. Mucoadhesive compounds
were evaluated based on their potential ability to increase
the residence time in the nasal cavity and, therefore, increase
the immune response elicited by a nasal vaccine. It was pro-
posed that maximal mucosal and systemic antibody production
would be elicited by a dry powder nasal vaccine formulation
containing whole inactivated influenza virus by increasing
the local residence time.
MATERIALS AND METHODS
Materials
Whole inactivated influenza virus (WIIV, H1N1 strain, A/PR/
8/34, Charles River SPAFAS, North Franklin, CT; Lot#4-
PRI000901, 2 mg/mL) was supplied as a liquid preparation.
D-(+)-trehalose dihydrate (referred to as trehalose), hydrox-
ypropyl methylcellulose (MW = 10 kD, HPMC LMW or
MW = 90 kD, HPMC-HMW), carboxymethylcellulose
sodium (MW = 90 kD, CMC LMWor MW = 700 kD, CMC-
HMW), and sodium alginate (SA, 200–400 cps) were pur-
chased (Sigma Chemical Co, St Louis, MO). Chitosan (Chit,
MW= 161 kD, degree of deacetylation = 92%) was graciously
donated (Vanson HaloSource, Bothell, WA).
SFD Powder Manufacture
Aqueous solutions containing 10% solids (trehalose alone
for residence time studies or 1:1000 WIIV:trehalose for im-
mune response studies) were passed through a sprayer (7 mm,
2-fluid nozzle diameter, Büchi Mini Spray-Dryer, B-191,
Flawil, Switzerland) at 10 mL/min with atomizing nitrogen gas
(back pressure 1 atm) to deliver the suspension at 500 L/hr.
Droplets collected in aluminum trays containing liquid nitro-
gen were lyophilized (manifold temperature –55-C, pressure
25 mtorr, 72 hours, Kinetics Flexi-Dry, Kinetics Thermal
Systems, Stone Ridge, NY).
Physico-chemical Characterization
Particle Morphology and Size Determination
Powders on double-sided adhesive carbon tabs in representa-
tive areas of stubs were photographed (n = 3).6 Each powder
was suspended in 2% Span 80 in light mineral oil and sub-
jected to laser diffraction particle size analysis (n = 3, Series
2600c, Malvern Instruments, Worcester, UK).6
Flow Property Assessment
Bulk/tapped densities and static angle of repose measure-
ments were conducted for sieved fractions of trehalose, bulk
and sieved MA, and SFD powders (n = 3). Density mea-
surements used ~10 mL of powder poured into a graduated
cylinder.22 Carr’s compressibility index (CCI) is calculated
from the bulked and tapped density measurements. Static
angle of repose measurement used ~10 mL of powder poured
through a glass funnel onto a flat collection surface where the
angle to the horizontal was measured.23
Surface Area Measurement
Single-point surface area analyses of sieved trehalose (1.5
to 1.75 g) and SFD (0.5 to 0.75 g) powders (Quantasorb Jr,
Quantachrome Corp, Boynton Beach, FL) were performed.
Weighed samples were degassed (25 mtorr, 60-C, 5 hours
with nitrogen) followed by repetitive adsorption and desorp-
tion of the adsorbate (30% nitrogen in helium).
Thermal Analysis
Moisture content determination was conducted (Mettler LJ16
Moisture Analyzer, Mettler-Toledo, Columbus, OH). Each
sample was loaded onto an aluminum tray coating the bottom
with a thin layer of powder, then heated to 150-C (n = 3).
Final versus initial powder weight was the water content in the
sample expressed as a percentage of the total weight. Dif-
ferential scanning calorimetry (Perkin Elmer DSC 6, Well-
esley, MA) was performed. SFD powders were pretreated at
60-C for 5 hours to determine if the powder manufactured
was amorphous. Analysis was performed between 50-C and
250-C. Ramp rates of 10-C per minute for bulk and 10-C
and 40-C for SFD trehalose were employed.
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Stability (Retention of Bioactivity)
WIIV was resuspended in HEPES-saline at a concentration
of 2 μg/mL. The hemagglutination assay (HA) titer for
the WIIV, as provided by the manufacturer, was 1:131,072
for 0.05 mL. Liquid preparation of WIIV from the vendor
was diluted to 2 μg/25 μL with sterile saline and sealed in
1.7-mL centrifuge tubes. About 5 mg total 25-μm SFD pow-
der for rat use containing 5 μg/5 mg trehalose was packed
into each gelatin capsule (#3, Capsugel, Greenwood, SC) and
sealed in a glass scintillation vial. Vials containing liquid or
powder samples were stored at 37-C and 80% relative hu-
midity (RH), 23-C and 40% RH, or 4-C and 50% RH. Sam-
ples were taken at intervals, for HA titers (compared with
starting sample, 0) up to 12 weeks (n = 2). Powder was re-
constituted with saline to 1 mg influenza virus/mL, based on
hemagglutinin (H) content. Fifty microliters of double serial-
diluted inactivated influenza virus samples were added to
wells containing 50 μL of 0.5% chicken red blood cells
(Charles River SPAFAS) and incubated at room temperature
(RT) for 1 hour for the HA assay. The end point HA titer was
the reciprocal of the largest influenza vaccine dilution show-
ing complete hemagglutination of chicken red blood cells.
In Vivo Characterization
Animal Care
Female Brown Norway rats (125 to 175 g, Charles River,
Raleigh, NC) were kept under standard conditions in Asso-
ciation for Assessment and Accreditation of Laboratory
Animal Care-approved facilities under Institutional Animal
Care and Use Committee-approved protocol (06–265.0-A)
in a controlled temperature (22-C ± 1-C) and light (12-hour
light and dark cycles) room with free access to food and
water. Prior to use rats were anesthetized by intraperitoneal
injection of 40 mg/kg ketamine, 2 mg/kg xylazine, and
0.75 mg/kg acepromazine.
Residence Time Study
Liquid saline formulations or 1% MA in saline containing
insoluble 99mTc-sulfur colloid (99mTc-SC) were delivered
(25 μL) into the right nostril of an anesthetized rat. To label
powder formulations, saline containing insoluble 99mTc-SC
was centrifuged at 13 201g for 10 minutes. Supernatant was
removed and the pellet was washed 3 times with ethanol.
The pellet was allowed to dry before being blended with
the rat SFD trehalose (with or without a MA) with a mortar
and pestle. Five-milligram quantities were placed in gelatin
capsules.
Powder formulations were delivered using compressed air
(20 psig), by solenoid valve and 200 μL pipette tip (Ep-
pendorf, Westbury, NY) containing the contents of 1 dosage
capsule) to the right nostril of the anesthetized rat. The time
points analyzed were 5, 15, and 120 minutes (n = 3) and 30,
60, and 180 minutes (n = 1). Rats were euthanized following
cardiac puncture by CO2 inhalation and nasal washes were
collected by cannulating the trachea and rapidly instilling
4 aliquots of 1.5 mL of sterile saline. Fluid passed from the
trachea through the nostrils was collected and analyzed in a
radioisotope calibrator (Model CRC-4, Capintech, Inc, Pitts-
burgh, PA). Estimates of dose were adjusted for radioactive
decay.
Residence time differences were assessed by regression
analysis (SigmaPlot, Systat Software, Inc., San Jose, CA).
A 2-compartment model was employed because there was
clear evidence of rapid removal of radioactivity from the
nasal cavity due to unhindered clearance followed by a grad-
ual elimination attributable to material sequestered in some
manner, perhaps adhered to mucus or epithelium. The particle
size (650 ± 60 nm) of the 99mTc-SC was too large to be ab-
sorbed through the nasal epithelium; the only means of eli-
mination was mucociliary clearance from the nasal cavity
and ingestion. The equation for modeling clearance was:
y ¼ aeð−btÞ þ ceð−dtÞ ð1Þ
where y is the radioactivity remaining and t is the time in
minutes. The model was fitted to the average value of rep-
licates and each individual point.
Vaccine Evaluation
Rats (n = 6/group) were immunized and boosted (intramus-
cularly [IM] 2 μg/100 μL liquid, IN 2 μg/25 μL liquid or
5 μg/5 mg powder on days 0 and 21). The actual dose de-
livered to the animal was 2 μg. SFD WIIV/trehalose was
prepared with 3% wt/wt CMC-HMW, SA, chitosan, or
HPMC-HMW.
Sample Collection
Blood samples obtained, under anesthesia; from the tail ar-
tery 3 weeks after vaccination were centrifuged (13 201g for
10 minutes); serum supernatant was removed and stored at
−80-C. Two weeks following the boost, rats were euthan-
ized by CO2 inhalation, following cardiac puncture. Nasal
washes were collected, by intubating the trachea and rapid-
ly instilling 1 mL of sterile saline, and subsequently stored
at −80-C.
Quantification of Antibody Response
Whole virus-specific antibody titers were determined by
enzyme-linked immunosorbent assay (ELISA). Plates (96-well,
Nalgen Nunc Maxisorb, Rochester, NY) were coated with
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100 μL of 1-μg/mL (based on total protein content as above)
whole inactivated influenza virus at 4-C overnight, then
blocked at 37-C for 1 hour with phosphate-buffered saline
(PBS) Tween 20 (PBST; Sigma) containing 5% nonfat dry
milk. After washing, serial dilutions of sera or nasal wash
(100 μL/well) were added and incubated at 37-C for 1 hour.
Plates were washed again, then incubated at 37-C for 45 min-
utes with horseradish peroxidase conjugated secondary anti-
bodies: goat anti-rat Ig (H+L) (Southern Biotechnology
Associates, Inc, Birmingham, AL) or goat anti-rat IgA (Bethyl
Laboratories, Montgomery, TX). Plates were developed by
incubating for 30 minutes at room temperature with 3,3′,5,5′-
tetramethyl benzidine substrate (Sigma). After stopping the
reaction using 0.5 M H2SO4, plates were read at 450 nm.
The end point titers were defined as the highest reciprocal
dilution of sera or nasal wash yielding an OD450 value at
least 3× background obtained using samples obtained before
immunization. All standards, samples, and controls were
analyzed in duplicate.
Statistical Analyses
Analysis of variance was performed on the logarithmic trans-
formation of vaccine titer values at α = 0.05 to determine any
differences between the dosing groups. For comparisons of
2 means, Scheffé’s method was used at α = 0.05.
RESULTS AND DISCUSSION
Particle Morphology and Size Determination
Figure 1 shows scanning electron micrographs of spherical,
porous SFD particles. SFD trehalose particles exhibited areas
of surface coating. This coating may be explained by rapid
solvent evaporation during the atomization process, transport-
ing dispersed solids to the surface, and subsequent removal
of solvent at the surface during lyophilization. However,
this mechanism requires further study.
The particle size distribution shown in Figure 2 indicates
modes at 4, 10, 20, and 40 μm, obtained by laser diffrac-
tion. The volume median diameter of the SFD trehalose
powder was 24.9 μm with a span of 1.5 μm. The volume
median diameter of the SFD powder was 26.9 μm with a
span of 1.3 μm. The volume median diameter of the SFD
powder containingWIIVwas 24.9 μm, with a span of 1.8 μm.
These powders do not exhibit statistically different median
sizes.
Flow Property Assessment
The flow properties can potentially affect the performance of
the final product. Free-flowing powders, in the size range of
relevance to nasal delivery, are easily blended and dispersed
as aerosols.
The bulk (~0.2 g/mL) and tapped (~0.2 g/mL) densities of
the SFD powder were significantly lower than bulk trehalose
(Table 1, ~0.5 and ~0.6 g/mL, respectively).
Large cohesive forces acting on a powder result in poor flow
properties and render it easily compressible (ie, the higher
the CCI). A free-flowing powder has a CCI less than ~20%
Figure 1. Scanning electron micrographs of spray-freeze-dried (SFD) trehalose for use at (A) ×60 magnification, (B) ×150
magnification, and (C) ×600 magnification.
Figure 2. Particle size distribution of spray-freeze-dried (SFD)
trehalose for use in rats.
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to 21%.24 The sieved trehalose (~20% to 23%) had a lower
CCI than the SFD trehalose (~35%). A large static angle of
repose is indicative of large cohesive forces within the pow-
der. As a guide, powders with static angles of repose less
than 40- are considered to be free-flowing powders; with
angles greater than 50-, the powders flow poorly or not at
all.25 Table 1 shows the angles of repose for the SFD and
sieved powders studied. The static angle of repose of SFD
(~36-) was larger than the sieved trehalose (~20- to 23-),
but both would be regarded as free flowing. The sieved
trehalose appeared to be free flowing when density and angle
of repose data were considered. The SFD data was equi-
vocal since CCI data seemed to contradict angle of repose
data. However, it is clear that sieved trehalose appeared to
flow more freely than SFD powder.
The ability of a powder to flow is one of the factors that
affect the mixing of different materials and formation of a
powder blend. Particle size, size distribution, shape, surface
texture, surface energy, chemical composition, moisture con-
tent, and other factors influence flow.26 This may be im-
portant for the blending of the virus and excipient with the
mucoadhesive compound. Also, because nasal delivery re-
quires a fluidization of the powder bed, it is conceivable that
flow properties of powders could affect the emitted dose
from the device and delivery of the vaccine.
Surface Area Measurement
The specific surface areas of the powders are shown in
Table 1. The SFD powder (~1.2 m2/g) exhibited significantly
greater surface area than the sieved trehalose (~0.5 m2/g).
This is consistent with the literature.9,11,27
Thermal Analysis
The moisture contents of the trehalose powders are shown
in Table 1. Moisture content was low in SFD powder be-
cause of the lyophilization process. Lyophilized powders gen-
erally have 3% to 5% moisture present. The sieved trehalose,
as a dihydrate, has greater moisture content (~10%) than the
SFD powders (~5%).
Differential scanning calorimetry scans of SFD powder and
bulk trehalose are shown in Figure 3. The characteristic
glass transition temperature (Tg) associated with the SFD
amorphous solids required removal of the moisture from the
powder. Consequently, powders were held at 60-C for 5 hours.
SFD trehalose powder exhibits a Tg at 117-C, a crystal-
lization peak at 174-C, and a sharp melting peak at 214-C,
consistent with that in the literature.28 The Tg of untreated
SFD trehalose could not be resolved with this instrument, and
further tests could be conducted with a modulated differential
Table 1. The Flow Properties, Specific Surface Area, and Moisture Content of Spray-Freeze-Dried (SFD) and Sieved Trehalose, Mean














SFD 0.17 (0.01) 0.26 (0.01) 34.8 (0.9) 36.1 (2.1) 1.25 5.39 (0.52)
Bulk sieved1 0.46 (0.01) 0.60 (0.01) 23.0 (1.3) 21.6 (1.5) 0.49 9.64 (0.06)
Figure 3. Differential scanning calorimetry of (A) spray-freeze-dried (SFD) and (B) bulk trehalose. After pretreated SFD samples were
heated to 250-C at 10-C/min and also scanned at 40-C/min to better resolve the Tg at ~110-C. Bulk trehalose was heated from room
temperature to 250-C at 10-C/min.
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scanning calorimeter. Bulk trehalose dehydrate exhibited a
sharp peak at 100-C, indicating removal of unbound surface
moisture, at ~120-C, bound water of crystallization was re-
moved. The melting peak can be seen at 214-C. Amorphous
powder was produced by SFD and the relatively high Tg in-
dicates that the trehalose should be stable under room tem-
perature storage and handling conditions.
Stability (Retention of Bioactivity)
The storage conditions in these experiments were approx-
imately those employed in regulated studies of refrigeration,
room, and accelerated storage (5-C ± 3-C, 25-C ± 2-C, and
60% ± 5% RH, 40-C ± 2-C and 75% ± 5% RH.29) as dic-
tated by existing laboratory equipment. At 4-C and 50% RH,
powder vaccine retained 100% of HA activity for the dura-
tion of the 12 weeks (Figure 4). However, the HA activity
of the liquid formulation under these conditions dropped to
75% after week 2. Similarly, at 23-C and 40% RH, the
powder vaccine retained 100% of HA activity, whereas the
HA activity of the liquid dropped to 50% at week 2 and was
further reduced to 25% of prestorage levels at week 8. The
powder formulation showed a drop in stability, to 75% at
week 2, 50% at week 4, and 6.25% at week 12, over time
under the accelerated storage conditions (37-C and 80% RH).
The powder formulation was more stable than the corre-
sponding liquid, which lost 100% of activity by week 8.
While not ideal, the vaccine storage stability exhibited by the
powder formulation was improved with respect to liquid.
The high Tg and low moisture content (G 3%) of the tre-
halose are 2 important factors in the increased stability of the
powder formulation. To ensure the long-term stability of a
biological macromolecules, particularly proteins and pep-
tides, as a dried solid, the Tg of the amorphous phase must
exceed the planned storage temperature.30,31 Since water is
a plasticizer of the amorphous phase, low residual moisture
is needed to ensure stability.32 The loss of activity seen un-
der accelerated conditions may be explained by the residual
moisture and large surface area of the SFD trehalose parti-
cles. Greater stability might be achieved by optimization of the
freeze-drying process with a shelf lyophilizer to lower the mois-
ture content of the powder. Additionally, greater stability could
be achieved with control of surface area as an objective in a
designed experiment. Increased surface area has been shown
to lead to a decrease in stability of vaccine formulations.33
In vivo characterization
Residence Time Study
Correlation coefficients and parameters (a, b, c, and d) re-
lated to the nasal clearance following intranasal delivery of
various formulations, determined by the regression analysis,
are shown in Table 2. All of the curves exhibited good fit
(R2 9 0.94). Parameters a and b are representative of initial
clearance of the radioactivity from the nasal cavity. They
compose the term of a 2-compartment intravenous (IV) bolus
equation that represents the distribution phase. With the ex-
ception of the liquid SA, the distribution constant (b) was
larger for the powder formulations than the liquids. This is
surprising because run-off and swallowing of the liquid for-
mulations, unhindered clearance, might be expected to ac-
count for a large, immediate decrease in the radioactivity.
However, viscosities of 1% HPMC-HMW and CMC-HMW
were much greater than 1% SA, which may explain the in-
crease in residence time.34 Powders least effecting viscosity
(trehalose alone and Chitosan with trehalose) cleared more
rapidly than other formulations.
Parameters c and d are indicative of mucociliary clearance
rate. They compose the term of a 2-compartment IV bolus
equation that represents the elimination phase. The elimi-
nation constant (d) was very similar for all of the liquid
formulations and powder No MA, CMC-HMW, and Chit,
while the powder HPMC-HMW and SA were significantly
lower. These results are expected because HPMC-HMWand
SA exhibited the greatest viscosity, when fully dissolved, and
swelling index, respectively.34 Based on the in vitro results,
Figure 4. Vaccine stability of liquid (open square) or powder (closed diamond) vaccine stored under (A) 4-C, 50% RH, (B) 25-C, 40%
RH, and (C) 37-C, 80% RH at different time points, compared with the week 0 sample. Each data point represents the mean of
duplicate samples.
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the powder CMC would be expected to have a lower elimi-
nation constant.
In vitro experiments were potential predictors of the effect
of MA on the residence time of liquid and powder prepa-
rations in the nasal cavity.34 Wettability of the powders was
determined by placing a drop of buffer on a compact of the
MA and measuring the contact angle. Dissolution rate of
powders was determined by exposing them to buffer and
measuring the viscosity over time with a capillary or cone
and plate viscometer in unstirred and stirred systems. Swell-
ing indices indicate the rate and amount of water uptake of
the powders and were measured by placing compacts of the
powders in buffer and measuring the weight gained by water
uptake as a function of time.
The contact angle of the HPMC-HMW and HPMC-LMW
(55- and 41-, respectively) were significantly greater than
the other polymers, indicating a prolonged dissolution time
(P G .05). For both the unstirred and stirred systems, the
viscosities of the CMC polymers and SAwere significantly
greater than the HPMC polymers (P G .05). The swelling
indices of CMC-HMW and SA (5.0 and 4.7, respectively)
were significantly greater than the other MA (P G .05).
Based on these in vitro properties, the rank order of MA on
increasing residence time is predicted to be SA, CMC-
HMW 9 Chitosan 9 HPMC-HMW.
The areas under the curve (AUC) are shown in Table 2.
The AUC of the liquid formulations were greater than the
powder formulations, with the exception of SA. However,
the AUCs except trehalose alone and HPMC trehalose were
similar (roughly 8000 to 10 000 μCi*min). The rank of the
AUC of the liquid formulations (CMC-HMW 9 HPMC-
HMW, SA 9 No MA) was consistent with the viscosities of
the 1% solutions (HPMC-HMW 9 CMC-HMW 9 SA 9 No
MA). However, it should be noted that larger viscosity does
not directly correlate to increased residence time (No MA,
with respect to, HPMC-HMW). The rank of the powder for-
mulations (SA 9 CMC-HMW, Chit 9 HPMC-HMW, No MA)
was consistent with the contact angle (Chit G CMC-HMW G
SA G HPMC-HMW), viscosity (unstirred at 60 minutes, SA 9
CMC-HMW 9 HPMC-HMW 9 Chit, No MA), and swelling
index (SI) at 60 minutes (CMC-HMW, SA 9 Chit 9 HPMC-
HMW 9 No MA).
Formulation Evaluation
After the initial vaccination, IM delivery of liquid vaccine
provided equivalent serum antibody titers to those obtained
by IN powder without MA, CMC-HMW, SA, and HPMC-
HMW, and significantly greater serum antibody titers than
IN liquid and IN powder with chitosan (Figure 5a, P G .05).
Table 2. Correlation Coefficient (r2) and Parameters Determined by Regression Analysis of 2-Compartment Model Curves Determined
by the % Radioactivity Remaining as a Function of Time
Liquid Formulations Powder Formulations
No MA HPMC-HMW CMC-HMW SA No MA HPMC-HMW CMC-HMW SA Chit
r2 0.99 0.96 0.97 0.97 0.94 0.99 0.94 0.99 0.95
a 43.06 28.41 34.26 16.82 51.88 72.86 43.80 51.19 34.32
b 0.06 0.21 0.09 46.35 480000 0.23 0.56 0.25 13000
c 55.33 72.03 63.95 83.18 48.12 27.34 56.20 48.67 65.68
d 0.003 0.004 0.002 0.006 0.006 0.000 0.003 0.000 0.005
AUC
(μCi*min)
8578 9290 10160 9018 5410 5056 7448 8972 7465
Figure 5. (A) Serum antibody titers (3 weeks after initial dosing [Bleed 1] and 2 weeks after boost [Bleed 2]) and (B) mucosal antibody
titers elicited after vaccination of vaccine dosed either intramuscularly (IM) or intranasaly (IN) in saline or IN powder with or without
3% wt/wt mucoadhesive compounds (MA) (n = 6, positive standard deviation).
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After boosting, IM delivery of liquid vaccine provided equi-
valent serum antibody titers to those obtained by IN liquid
and IN powder with No MA, CMC-HMW, SA, and HPMC-
HMW, and significantly greater serum antibody titers than IN
powder with chitosan (P G .05). After the initial vaccination,
IN liquid vaccine provided equivalent serum antibody titers
to those obtained by IN powder without MA, CMC-HMW,
SA, chitosan, and HPMC-HMW. After boosting, IN liquid
provided significantly greater serum antibody titers than IN
powder with chitosan and was equivalent to all other for-
mulations (P G .05). All antibody responses elicited were
significantly greater than naïve serum (P G .05).
Initial studies of the formulation (WIIV and trehalose were
freeze-dried, milled, sieved to 45- to 125-μm particles and
blended with chitosan) and nasal dosing of a dry powder
influenza vaccine to rats has been described elsewhere.6,7
Antibody responses were elicited by 100 μg powder vaccine
that generated strong nasal mucosal and systemic immune
responses. The chitosan mucoadhesive powder formulation
generated significantly greater antibody titers compared with
IM injection, IN liquid, or IN powder without mucoadhesive
formulations at this dosing level after initial vaccination.
Similar serum antibody titers were seen in chitosan muco-
adhesive powder, IM injection, and IN liquid. Comparable
nasal IgA titers were generated in the IN groups containing
antigen, while no nasal IgA response was seen in animals
dosed IM or with excipients alone intranasally.
In the present experiments, similar serum antibody levels to
the previous study were achieved after dosing IN liquid
2 μg H after the initial vaccination and boosting and the
IM after boosting to the previous experiment. However, a
10-fold higher response was generated by IM injection after
initial vaccination than the previous experiment. The IN pow-
der containing chitosan elicited a 10-fold higher response af-
ter the initial vaccination, but a comparable response after
boosting. One possible explanation for this could be due to
a potential adjuvant effect caused by impurities in the chi-
tosan. In the present studies, highly purified (G 2% impu-
rities) chitosan was blended with the WIIV-SFD particles.
This chitosan did not require cryo-milling to produce par-
ticles in the desired size range. MA used in the present study
was assayed to quantify for the presence of endotoxin. There
was no more than 0.11 ng of endotoxin present in the MA in
any dose of vaccine, an order of magnitude lower than nor-
mally administered as an adjuvant.35 In both the previous
and current studies, after initial vaccination and a boost, com-
parable serum antibody levels were seen when dosed IM,
IN liquid, or IN powder with MA. Hemmaglutination inhib-
ition (HAI) titers and IgG isotyping also displayed a similar
pattern of response as ELISA (data not shown).
Substantial IgA titers were seen in all rats after intranasal
immunization (Figure 5b). All of the nasal IgA titers elic-
ited from nasal formulations were significantly greater than
IM injection except for IN powder with chitosan (P G .05).
There were no statistically significant differences seen be-
tween any of the IN formulations. The production of a
mucosal immune response in the form of IgA production
demonstrates that intranasal delivery of the WIIV will pro-
duce both a local and systemic immune response.
One powder, containing SA, was shown to have an increased
residence time in the nasal cavity. No statistically signifi-
cant differences were noted between formulations in elicit-
ing both IgA and IgG responses. However, the trend was that
SA elicited the highest IgA response of all treatments
including solution. Even as it elicited one of the higher IgG
responses, arguably the trehalose alone and liquid treatments
elicited greater responses. While trends in the immune re-
sponses may be interpreted to support the original hypothesis,
powder preparations containing WIIV were not statistically
different in their effect.
CONCLUSIONS
Maximal mucosal and systemic antibody production would
be elicited by an IN powder with SA, equivalent to IM in-
jection. The experiments described address the potential to
overcome cold chain requirements (needed for vaccine
stability) and to provide single-use, nonrefillable delivery
technologies that require minimal training. An inactivated,
heat-stable, unit-dose vaccine was developed that elicited a
systemic immune response in Brown Norway rats compara-
ble to, and a local mucosal response superior to, IM injection.
The latter observation indicates a benefit when used for in-
fluenza prevention, since the virus enters the host by this
route. Further development of this approach may ultimately
provide a safe and an effective alternative to the currently
available influenza vaccines.
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